Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Why IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket

Published 14/10/2022, 12:34
Updated 14/10/2022, 13:40
© Reuters.  Why IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket

Gainers

  • Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 80.1% to $0.4161 in pre-market trading after declining around 7% on Thursday. CONNEXA, last month, announced a $5.0 million private placement.
  • Zovio Inc (NASDAQ: ZVO) rose 16.8% to $0.1690 in pre-market trading.
  • Eargo, Inc. (NASDAQ: EAR) rose 16.5% to $0.8269 in pre-market trading. Eargo announced that the record date for its proposed rights offering is October 24, 2022.
  • FedNat Holding Company (NASDAQ: FNHC) rose 16.3% to $0.4089 in pre-market trading after jumping over 56% on Thursday.
  • IMARA Inc. (NASDAQ: IMRA) rose 13.2% to $2.92 in pre-market trading. Enliven Therapeutics and Imara announced a merger agreement.
  • Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares rose 10.3% to $2.68 in pre-market trading after declining over 4% on Thursday.
  • WM Technology, Inc. (NASDAQ: MAPS) shares rose 9.9% to $1.88 in pre-market trading.
  • Quanergy Systems, Inc. (NYSE: QNGY) shares rose 9.3% to $2.00 in pre-market trading after dipping 16% on Thursday.
  • CarLotz, Inc. (NASDAQ: LOTZ) rose 8% to $0.29 in pre-market trading.
  • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) rose 7.7% to $3.47 in pre-market trading.
  • Digital Brands Group, Inc. (NASDAQ: DBGI) shares rose 7.3% to $0.1180 in pre-market trading after the company finalizes new agreement for $20 million revenue Sunnyside, LLC acquisition, scheduled to close in November.
  • Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) rose 7.1% to $1.36 in pre-market trading after declining over 5% on Thursday.
  • Zai Lab Limited (NASDAQ: ZLAB) rose 6% to $30.20 in pre-market trading. Seagen and Zai Lab recently announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Losers

  • Novo Integrated Sciences, Inc. (NASDAQ: NVOS) fell 38.7% to $0.46 in pre-market trading after the company announced pricing of $2 million public offering of 4 million units at $0.50 per unit.
  • Nuwellis, Inc. (NASDAQ: NUWE) fell 13.3% to $0.2880 in pre-market trading after dropping 10% on Thursday. Nuwellis recently announced results of the AVOID-HF clinical study analysis at the 2022 HFSA meeting, showing a "statistically superior clinical benefit of Aquadex therapy in reducing heart failure events and mortality."
  • Nutex Health Inc. (NASDAQ: NUTX) fell 10.8% to $0.8512 in pre-market trading after jumping 72% on Thursday. Nutex recently provided a corporate update.
  • Gravitas Education Holdings, Inc. (NYSE: GEHI) shares fell 9.2% to $13.62 in pre-market trading after surging around 14% on Thursday.
  • Romeo Power, Inc. (NYSE: RMO) shares fell 8.7% to $0.33 in pre-market trading. Nikola completed exchange offer to acquire Romeo Power common stock.
  • Oblong, Inc. (NASDAQ: OBLG) shares fell 7.7% to $0.2123 in pre-market trading after climbing over 26% on Thursday.
  • Qualigen Therapeutics, Inc (NASDAQ: QLGN) fell 7.1% to $0.2510 in pre-market trading.
  • Plus Therapeutics, Inc. (NASDAQ: PSTV) fell 6.7% to $0.4750 in pre-market trading. JonesTrading, last week, initiated coverage on the stock with a Buy rating and $5 price target.
  • China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares fell 6.6% to $0.6180 in pre-market trading. On October 11, China SXT Pharmaceuticals received the funds from Mr. Xiao who previously agreed to purchase 1,625,798 shares of the company, par value $0.08/share at a per share purchase price of $1.35.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.